After updating investors this week on its strategy for tackling the blockbuster market for cholesterol lowering drugs, shares in Esperion Therapeutics (NASDAQ: ESPR) are rocketing higher. Here's how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results